• Corpus ID: 219573356

Predicting inhibitors for SARS-CoV-2 RNA-dependent RNA polymerase using machine learning and virtual screening

  title={Predicting inhibitors for SARS-CoV-2 RNA-dependent RNA polymerase using machine learning and virtual screening},
  author={R. M. M. Cozac and Nazim Medzhidov and Shinya Yuki Elix and Inc. and Tokyo and Japan.},
  journal={arXiv: Quantitative Methods},
Global coronavirus disease pandemic (COVID-19) caused by newly identified SARS- CoV-2 coronavirus continues to claim the lives of thousands of people worldwide. The unavailability of specific medications to treat COVID-19 has led to drug repositioning efforts using various approaches, including computational analyses. Such analyses mostly rely on molecular docking and require the 3D structure of the target protein to be available. In this study, we utilized a set of machine learning algorithms… 

Tables from this paper

Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
The modelling approach successfully identified multiple drugs with potential activity against SARS-CoV-2 RdRp, and these top hits may not only have utility in treating COVID-19 but may provide a useful starting point for therapeutics against other coronaviruses.
Repurposing of FDA‐approved drugs against active site and potential allosteric drug‐binding sites of COVID‐19 main protease
This systematic and efficient computational analysis successfully determines ivermectine, diosmin and selinexor currently subjected to clinical trials, and further proposes bromocriptine, elbasvir as Mpro inhibitor candidates to be evaluated against SARS-CoV-2 infections.
Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies
It is shown how a fast and robust computational process can be used to screen large libraries of drugs and natural compounds to identify those that may inhibit the main protease of SARS-Cov-2 (3CL pro, Mpro).
Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
This publication is an e-print and is also available on arXiv, where it should not be relied upon without context to guide clinical practice or health-related behavior.


Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
It is proposed that the clinically observed resistance of SARS to ribavirin is probably due to perturbation of the conserved motif A that controls rNTP binding and fidelity of polymerization, and suggested that designing anti-SARS therapies can benefit from successful experiences in design of other antiviral drugs.
Insights into RNA-dependent RNA Polymerase Inhibitors as Anti-influenza Virus Agents.
An overview of the most interesting RdRp inhibitors that have appeared in the literature since 2000 is presented, and a selection of inhibitors endowed with different scaffolds are described, along with the main features responsible for their activity.
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
The findings suggest that the virus is evolving and European, North American and Asian strains might coexist, each of them characterized by a different mutation pattern.
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
The structure of the COVID-19 virus polymerase essential for viral replication provides a basis for the design of new antiviral drugs that target viral RdRp, also named nsp12, and it appears to be a primary target for the antiviral drug remdesivir.
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
High-resolution crystal structures of the receptor-binding domain of the spike protein of SARS-CoV-2 and SARS -CoV in complex with ACE2 provide insights into the binding mode of these coronaviruses and highlight essential ACE2-interacting residues.
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase
  • R. Gentles
  • Biology
    HCV: The Journey from Discovery to a Cure
  • 2018
The discovery of beclabuvir occurred through an iterative series of structure-activity relationship studies directed at the optimization of a novel class of indolobenzazepines, identified as having superior antiviral, safety, and pharmacokinetic properties.
The trinity of COVID-19: immunity, inflammation and intervention
The interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression is described and the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation are highlighted.
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
Binformatics analysis on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes provide the basis for starting further studies on the pathogenesis, and optimizing the design of diagnostic, antiviral and vaccination strategies for this emerging infection.
Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: influenza life-cycle and currently available drugs
This review focuses on the influenza lifecycle and on the currently available drugs, while potential antiviral compounds for the prevention and treatment of influenza are considered in the subsequent review.
The Molecular Biology of Coronaviruses
  • P. Masters
  • Biology, Medicine
    Advances in Virus Research
  • 2006
This review summarizes both classical and contemporary discoveries in the study of the molecular biology of these infectious agents, with particular emphasis on the nature and recognition of viral receptors, viral RNA synthesis, and the molecular interactions governing virion assembly.